Ferring Pharmaceuticals, USA today received approval from the U.S. Food and Drug Administration (FDA) for degarelix, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, ...

CS21 was a three-arm, randomized (1:1:1), open-label, parallel-group Phase III trial of 12 months' duration incorporating adult male patients with histologically confirmed adenocarcinoma of the ...

FDA has approved the trade name Firmagon for degarelix for injection, a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of advanced prostate cancer. “This ...

To earn CME related to this news article, click here. January 9, 2009 — The US Food and Drug Administration (FDA) has approved fludarabine phosphate tablets for the treatment of B-cell chronic ...

Degarelix, being injectable, frequently causes injection-site reactions, which affect up to 40% of patients. 8 These reactions often result in irritation and occasionally cause small bumps at the ...

Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group Premenopausal women with ...

WEST DRAYTON, England, 17 June, 2014 – Ferring Pharmaceuticals confirmed today that FIRMAGON® (degarelix) will be the subject of an appeal hearing by the National Institute for Health and Care ...

More than 95 per cent of men who took degarelix for prostate cancer saw their testosterone levels fall dramatically as early as three days after they started treatment, according to a new article.

FDA approves Mozobil for non-Hodgkin lymphoma and myeloma, and Degarelix for advanced prostate cancer. The Food and Drug Administration approved Mozobil (plerixafor) in December for patients with ...

...ALP suppression was significantly greater in the degarelix group than in the leuprolide group... Gonadotropin-releasing hormone (GnRH) receptor agonists, such as leuprolide, are the most commonly ...